{
  "denotations": [
    {
      "id": "T2",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 8,
        "end": 27
      }
    },
    {
      "id": "T3",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 0,
        "end": 5
      }
    },
    {
      "id": "T5",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 71,
        "end": 78
      }
    },
    {
      "id": "T6",
      "obj": "Chemical",
      "span": {
        "begin": 188,
        "end": 197
      }
    },
    {
      "id": "T7",
      "obj": "Disease",
      "span": {
        "begin": 237,
        "end": 240
      }
    },
    {
      "id": "T10",
      "obj": "Chemical",
      "span": {
        "begin": 162,
        "end": 197
      }
    },
    {
      "id": "T11",
      "obj": "Disease",
      "span": {
        "begin": 223,
        "end": 234
      }
    },
    {
      "id": "T12",
      "obj": "Chemical",
      "span": {
        "begin": 162,
        "end": 182
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "24672032_3",
  "text": "IFNL3 ( lambda-3 interferon gene ) polymorphisms and the expression of miR-122 have been associated with sustained virological response ( SVR ) to treatment with pegylated interferon plus ribavirin in patients with chronic hepatitis C ( CHC ) ."
}
